175 related articles for article (PubMed ID: 20362363)
1. [The pharmacogenetics of vitamin K antagonists: still a matter for discussion].
Moreau C; Siguret V; Loriot MA
Rev Med Interne; 2010 May; 31(5):361-8. PubMed ID: 20362363
[TBL] [Abstract][Full Text] [Related]
2. [Vitamin K antagonists: from discovery to pharmacogenetics].
Moreau C; Loriot MA; Siguret V
Ann Biol Clin (Paris); 2012 Oct; 70(5):539-51. PubMed ID: 23047901
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacogenetics of oral anticoagulants: individualized drug treatment for more efficacy and safety].
Loriot MA; Beaune P
Rev Prat; 2007 Jun; 57(12):1281-6. PubMed ID: 17717937
[TBL] [Abstract][Full Text] [Related]
4. [Impact of pharmacogenetics on interindividual variability in the response to vitamin K antagonist therapy].
Siguret V
Pathol Biol (Paris); 2007 Jul; 55(6):295-8. PubMed ID: 17611042
[TBL] [Abstract][Full Text] [Related]
5. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.
Oldenburg J; Bevans CG; Fregin A; Geisen C; Müller-Reible C; Watzka M
Thromb Haemost; 2007 Sep; 98(3):570-8. PubMed ID: 17849045
[TBL] [Abstract][Full Text] [Related]
6. In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes.
Nowak-Göttl U; Dietrich K; Schaffranek D; Eldin NS; Yasui Y; Geisen C; Mitchell LG
Blood; 2010 Dec; 116(26):6101-5. PubMed ID: 20833980
[TBL] [Abstract][Full Text] [Related]
7. [Optimalisation of treatment with vitamin K antagonists--the role of gene polymorphisms].
Stępień E; Wypasek E; Branicka A; Undas A
Kardiol Pol; 2010; 68 Suppl 5():S428-35. PubMed ID: 22134997
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic tests could be helpful in predicting of VKA maintenance dose in elderly patients at treatment initiation.
Kovac MK; Rakicevic LB; Kusic-Tisma JS; Radojkovic DP
J Thromb Thrombolysis; 2013 Jan; 35(1):90-4. PubMed ID: 22763922
[TBL] [Abstract][Full Text] [Related]
9. [Oral anticoagulation and pharmacogenetics: importance in the clinical setting].
Benusiglio PR; Desmeules J; de Moerloose P; Dayer P
Rev Med Suisse; 2007 Sep; 3(124):2030, 2033-4, 2036. PubMed ID: 17955831
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of vitamin K antagonists: useful or hype?
Lippi G; Franchini M; Favaloro EJ
Clin Chem Lab Med; 2009; 47(5):503-15. PubMed ID: 19397481
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics aspects of oral anticoagulants therapy.
Militaru FC; Vesa SC; Pop TR; Buzoianu AD
J Med Life; 2015; 8(2):171-5. PubMed ID: 25866574
[TBL] [Abstract][Full Text] [Related]
12. The pharmocogenomics of warfarin: closing in on personalized medicine.
Rettie AE; Tai G
Mol Interv; 2006 Aug; 6(4):223-7. PubMed ID: 16960144
[TBL] [Abstract][Full Text] [Related]
13. Influence of proton pump inhibitors and VKORC1 mutations on CYP2C9-mediated dose requirements of vitamin K antagonist therapy: a pilot study.
Brunner-Ziegler S; Jilma B; Magirr D; Sunder-Plassmann R; Giurgea GA; Hammer A; Margeta C; Brunner M; Koppensteiner R; Mannhalter C
Br J Haematol; 2014 Nov; 167(4):547-53. PubMed ID: 25142093
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of warfarin: current status and future challenges.
Wadelius M; Pirmohamed M
Pharmacogenomics J; 2007 Apr; 7(2):99-111. PubMed ID: 16983400
[TBL] [Abstract][Full Text] [Related]
15. [Genetic predisposition to bleeding during oral anticoagulants treatment].
Montes Díaz R; Nantes O; Molina E; Zozaya J; Hermida J
An Sist Sanit Navar; 2008; 31(3):247-57. PubMed ID: 19165291
[TBL] [Abstract][Full Text] [Related]
16. [Association between CYP2C9 and VKORC1 genetic polymorphism and warfarin dose requirements].
Yang J; Miao LY; Huang CR; Shen ZY; Jiang WP
Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Feb; 36(2):137-40. PubMed ID: 19099951
[TBL] [Abstract][Full Text] [Related]
17. Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin.
Siguret V; Pautas E; Gouin-Thibault I
Vitam Horm; 2008; 78():247-64. PubMed ID: 18374198
[TBL] [Abstract][Full Text] [Related]
18. Genetic causes of resistance to vitamin K antagonists in Polish patients: a novel p.Ile123Met mutation in VKORC1 gene.
Wzorek J; Wypasek E; Awsiuk M; Potaczek DP; Undas A
Blood Coagul Fibrinolysis; 2018 Jul; 29(5):429-434. PubMed ID: 29794812
[TBL] [Abstract][Full Text] [Related]
19. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
[TBL] [Abstract][Full Text] [Related]
20. [Warfarin resistance and related pharmacogenetic information].
Takahashi H
Brain Nerve; 2008 Nov; 60(11):1365-71. PubMed ID: 19069171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
